VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
XFORX4 Pharmaceuticals, Inc.$3.88$490M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksXFOREarnings History

XFOR logoX4 Pharmaceuticals, Inc. (XFOR) Earnings History

Net Loss

11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$100M
● Net Loss
TTM EPS (Diluted)
$-0.79
Per share, diluted
YoY EPS Growth
+66.5%
Excellent
Net Margin
-225.6%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-247.4%
Gross Margin82.2%
Return on Equity-76.0%
Return on Assets-36.3%
Record Annual Net Income-$13MFY2015
Record Quarterly EPS$13.57Q2 2024
Consecutive Profitable Years0years
Q1 2026
Net Income-$20M
EPS (Diluted)$-0.16
YoY Growth+66.5%Excellent
QoQ Growth+15.4%Strong

Loading earnings history...

X4 Pharmaceuticals, Inc. (XFOR) Earnings Overview

As of June 12, 2026, X4 Pharmaceuticals, Inc. (XFOR) reported trailing twelve-month net income of -$100M, reflecting +66.5% year-over-year growth. The company earned $-0.79 per diluted share over the past four quarters, with a net profit margin of -225.6%.

Looking at the long-term picture, XFOR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2015.

X4 Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including CYCN (-$5M net income, -170.1% margin), PRAX (-$327M net income), KYMR (-$315M net income, -794.4% margin), XFOR has room to improve margins relative to the peer group. Compare XFOR vs CYCN →

XFOR Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
XFOR logoXFORCurrent
-$100M$-0.79-225.6%-76.0%+66.5%—
CYCN logoCYCN
-$5M$-1.25-170.1%-39.3%+9.9%
PRAX logoPRAX
-$327M$-11.31--45.8%-32.0%
KYMR logoKYMR
-$315M$-3.23-794.4%-25.8%-23.8%
IMVT logoIMVT
-$506M$-2.48--64.8%-1.5%
ARDX logoARDX
-$58M$-0.24-15.1%-36.2%-52.9%
Best in group
Lowest in group

XFOR Historical Earnings Data (2015–2025)

11 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$79M-111.5%-$87M$-1.87-225.6%-247.4%
2024-$37M+63.0%-$36M$-5.59-1464.6%-1423.6%
2023-$101M-7.8%-$108M$-17.07--
2022-$94M-5.8%-$88M$-45.60--
2021-$89M-42.8%-$75M$-119.58--
2020-$62M-17.7%-$60M$-92.84-2071.0%-1995.8%
2019-$53M-58.7%-$47M$-138.94--
2018-$33M+1.7%-$29M$-14238.00--
2017-$34M-47.5%-$36M$-17767.00--
2016-$23M-73.8%-$24M$-1737.74--
2015-$13M--$15M$-1266.46--

Download Data

Export XFOR earnings history in CSV or JSON format

Free sign-in required to download data

What if you invested $1,000 in XFOR back in 2015?

Total return with dividends reinvested · 11+ years of data

Calculate Returns

How much would $100/month in XFOR be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is XFOR Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

XFOR vs LLY — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.

Compare Now

XFOR — Frequently Asked Questions

Quick answers to the most common questions about buying XFOR stock.

What is XFOR earnings per share (EPS)?

XFOR trailing twelve-month (TTM) diluted EPS is $-0.79, reflecting +66.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.

What is X4 Pharmaceuticals, Inc.'s net income?

X4 Pharmaceuticals, Inc. (XFOR) trailing twelve-month net income is $-100M as of 2025. Earnings grew +66.5% year-over-year.

Is XFOR profitable?

XFOR is not currently profitable on a TTM basis, reporting a net loss of $-100M. Net margin is -225.6%. Investors should monitor for a return to profitability.

What is XFOR's earnings growth rate?

XFOR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.

What are XFOR's profit margins?

X4 Pharmaceuticals, Inc. net profit margin is -225.6%, operating margin is -247.4%, and gross margin is +82.2%. Below-average margins reflect competitive or cost pressures. Return on Equity is -76.0%.

Is XFOR growing earnings?

Yes, XFOR earnings are accelerating — EPS growth of +66.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-100M. Earnings momentum is strengthening.

What was XFOR's best earnings year?

X4 Pharmaceuticals, Inc.'s highest annual net income on record is $-13M, achieved in fiscal year 2015. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.

What were XFOR's earnings last quarter?

XFOR's most recent reported quarter was Q1 2026. Net income was $-20M with diluted EPS of $-0.16. For a full breakdown of all quarters, see the quarterly earnings table on this page.

XFOR Earnings Over Time (2015–2025)

Net income & EPS — annual and quarterly view